Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$39.92 -0.2%	$33.85	$23.42 ▼ $62.58	$2.32B	0.73	657,092 shs	429,889 shs
KNSA Kiniksa Pharmaceuticals International	$28.42 -2.1%	$27.90	$17.82 ▼ $30.69	$2.12B	0.05	559,497 shs	492,519 shs
SRPT Sarepta Therapeutics	$13.32 -5.3%	$28.42	$12.60 ▼ $150.48	$1.38B	0.45	2.80 million shs	23.94 million shs
TBPH Theravance Biopharma	$11.35 +0.9%	$10.47	$7.44 ▼ $11.88	$562.51M	-0.02	256,992 shs	153,209 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-0.20%	+1.76%	+16.01%	+42.57%	-14.35%
KNSA Kiniksa Pharmaceuticals International	-2.07%	-1.32%	-0.07%	+41.96%	+33.87%
SRPT Sarepta Therapeutics	-5.33%	-30.73%	-33.67%	-77.54%	-90.85%
TBPH Theravance Biopharma	+0.89%	-1.05%	+6.77%	+21.91%	+18.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3719 of 5 stars	3.4	3.0	4.3	2.3	0.8	1.9
KNSA Kiniksa Pharmaceuticals International	3.4203 of 5 stars	3.5	4.0	0.0	2.4	3.3	0.6
SRPT Sarepta Therapeutics	4.7827 of 5 stars	4.2	2.0	4.2	2.8	1.7	2.5
TBPH Theravance Biopharma	1.552 of 5 stars	3.3	0.0	0.0	1.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.71	Moderate Buy	$58.60	46.79% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$39.67	39.57% Upside
SRPT Sarepta Therapeutics	2.31	Hold	$53.50	301.65% Upside
TBPH Theravance Biopharma	2.67	Moderate Buy	$16.60	46.26% Upside

Current Analyst Ratings Breakdown

Latest TBPH, KNSA, AGIO, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	SRPT Sarepta Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$70.00 ➝ $50.00
7/21/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/21/2025	SRPT Sarepta Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/21/2025	SRPT Sarepta Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$32.00 ➝ $18.00
7/21/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
7/21/2025	SRPT Sarepta Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/21/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$40.00 ➝ $14.00
7/21/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $20.00
7/18/2025	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/18/2025	SRPT Sarepta Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$28.00 ➝ $20.00
7/18/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $41.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	63.35	N/A	N/A	$27.02 per share	1.48
KNSA Kiniksa Pharmaceuticals International	$423.24M	4.90	N/A	N/A	$6.60 per share	4.31
SRPT Sarepta Therapeutics	$1.90B	0.69	$2.30 per share	5.78	$15.99 per share	0.83
TBPH Theravance Biopharma	$65.27M	8.70	N/A	N/A	$3.57 per share	3.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	3.55	N/A	N/A	1,798.26%	-2.75%	-2.52%	7/31/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	113.68	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	0.00	1.22	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	-$1.18	N/A	32.43	N/A	-89.38%	-32.37%	-16.48%	8/4/2025 (Estimated)

Latest TBPH, KNSA, AGIO, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	N/A	N/A	N/A	$530.66 million	N/A
8/4/2025	Q2 2025	TBPH Theravance Biopharma	-$0.12	N/A	N/A	N/A	$16.04 million	N/A
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	N/A	N/A	N/A	$9.46 million	N/A
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	TBPH Theravance Biopharma	-$0.11	-$0.27	-$0.16	-$0.27	$28.08 million	$15.39 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	18.50	17.93
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
SRPT Sarepta Therapeutics	1.00	4.02	2.46
TBPH Theravance Biopharma	N/A	4.77	4.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
KNSA Kiniksa Pharmaceuticals International	53.95%
SRPT Sarepta Therapeutics	86.68%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
KNSA Kiniksa Pharmaceuticals International	53.48%
SRPT Sarepta Therapeutics	7.70%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	55.06 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable
TBPH Theravance Biopharma	110	50.00 million	46.55 million	Optionable

TBPH, KNSA, AGIO, and SRPT Headlines

Recent News About These Companies

Theravance Biopharma (NASDAQ:TBPH) Sets New 12-Month High - Here's Why

July 18, 2025 | marketbeat.com

Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60

July 17, 2025 | americanbankingnews.com

Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 10,000 Shares of Stock

July 16, 2025 | marketbeat.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16, 2025 | zacks.com

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen

July 14, 2025 | americanbankingnews.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 12, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Downgraded to "Hold" Rating by Wall Street Zen

July 12, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Trading Up 5.7% on Analyst Upgrade

June 27, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Price Target Raised to $25.00 at BTIG Research

June 27, 2025 | marketbeat.com

TBPH Theravance Biopharma, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

June 26, 2025 | prnewswire.com

Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 24,000 Shares of Stock

June 5, 2025 | insidertrades.com

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

June 3, 2025 | zacks.com

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

June 2, 2025 | marketwatch.com

Theravance hands off the last of its Trelegy royalties to GSK for $225M

June 2, 2025 | fiercepharma.comF

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...

June 2, 2025 | gurufocus.com

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...

June 2, 2025 | gurufocus.com

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

June 2, 2025 | prnewswire.com

Theravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and Ampreloxetine

May 21, 2025 | investing.com

Theravance Biopharma to Participate in an Upcoming Investor Conference

May 13, 2025 | prnewswire.com

Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Collegium Pharmaceutical (COLL) and Theravance Biopharma (TBPH)

May 11, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH, KNSA, AGIO, and SRPT Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$39.92 -0.08 (-0.20%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$39.92 0.00 (0.00%)

As of 07/21/2025 06:13 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.42 -0.60 (-2.07%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$27.99 -0.43 (-1.51%)

As of 07/21/2025 05:38 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Sarepta Therapeutics NASDAQ:SRPT

$13.32 -0.75 (-5.33%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$12.20 -1.12 (-8.42%)

As of 07/21/2025 08:00 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Theravance Biopharma NASDAQ:TBPH

$11.35 +0.10 (+0.89%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$11.33 -0.02 (-0.18%)

As of 07/21/2025 04:04 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time